INTRODUCTION
The most commonly used definition of evidence-based medicine (EBM) is the conscientious, explicit, and judicious use of current best evidence in making decisions about the care of the individual patients. The practice of evidence-based medicine means integrating individual clinical expertise with the best available external clinical evidence from systematic research. In 1997 the Committee of Ministers of the Council of Europe recommended the evidence-based guidelines implementing the quality improving system. Clinical practice guidelines aim to for improve the quality of health care delivery and strengthen the position of the patient. According to the definition of the Institute of Medicine, clinical practice guidelines (CPGs) are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. There is an exponentially rising interest toward CPGs in the medical literature and several organisations developed methodological manuals or so-called "Guidelines for guidelines". We found only one relevant narrative review in the literature, initiated by the Committee on Evidence-based Laboratory Medicine of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), which adapted methods of evidence-based guideline development to the field of laboratory medicine. This review provided an algorithm for the development process and defined specific reporting standards related to the laboratory aspects of diagnostic recommendations. Although methods for systematic reviewing of the literature and for the development of evidencebased recommendations, particularly in the field of therapeutics have been published and harmonised, the methodological quality of practice guidelines has been widely criticized. Most of these CPGs made therapeutic recommendations. Quality of CPGs in diagnostic fields and their impact in practice has been less well studied.
AIMS AND OBJECTIVES
For our aims we addressed the following key questions:
• Is there an easily applicable tool for the assessment of the quality diagnostic CPGs?
• What is the methodological quality of CPGs especially that of laboratory related recommendations?
• Are diagnostic and therapeutic CPGs different in their methodological quality?
• Is there any relationship between the characteristics and methodological quality of diagnostic CPGs?
• Do diagnostic CPGs meet basic reporting standards?
• Is there any correlation between methodological quality and validity of content of CPGs?
METHODS

4.1.
Topic selection, search and selection strategy of clinical practice guidelines For our investigations we have chosen two public health priority areas that have implications for laboratory medicine. One of them was the management of diabetes mellitus (DM). The other topic was related to oncology and focused on the management of non-small-cell-lung-cancer (NSCLC) patients. Systematic literature search was carried out in PubMed, in dedicated CPG databases and websites of professional to retrieve diagnostic CPGs published in English between 1 January 1999 and 31 December 2007. Two independent reviewers selected 26 DM and 11 NSCLC CPGs (Figure1) . 
Figure 1 Selection of CPGs
Appraisal tool and its applicability to diagnostic guidelines (Paper I)
We chose the AGREE Instrument a standardized, generic and validated checklist for the evaluation of the methodological quality of CPGs. In order to test the applicability of AGREE Instrument to diagnostic CPGs and to pilot test the use of this appraisal tool, we selected 4 most commonly cited and used primarily diagnostic CPGs for DM. Each CPG was independently evaluated by seven assessors and we assessed the agreement between reviewers by statistical methods (Cronbach's alpha, Interclass correlations (ICC)). The four guidelines were compared using one-way ANOVA and ANOVA using repeated measurements. The level of significance was defined at p<0.05.
Method of appraisal of diabetes mellitus and non-small cell lung cancer
guidelines using the AGREE Instrument Each CPG was appraised by 4 trained assessors by the AGREE Instrument as described in its manual. We assessed fulfilment of 23 criteria (I) grouped into 6 domains on a 4-point Likert scale and calculated Domain Scores (DS) in percentages, than judged overall performance of CPGs with one of 4 options. We appraised the methodological quality of NSCLC CPGs in this way, except for we changed the overall assessment terminology of AGREE ("strongly recommend", "recommend with provisos or alterations", "would not recommend", "unsure") to "very good", "good", "not so good", or "dubious" because we thought that this would lead to an easier understanding of the relation of methodological quality and content validity.
4.3.
Statistical methods 4.3.1. Correlation between the characteristics and methodological quality of clinical practice guidelines We created subgrouped DM CPGs based on their source, scope, length, origin and whether they were supplemented with a guideline methods manual. We also investigated the quality of guidelines according to the date and type of publication. In the statistical analyses, the mean item (I) and standardized domain scores (DS) of CPG subgroups were compared by the Kruskal -Wallis test. The level of significance was set at p ≤0.01 because of multiple comparisons. All analyses were performed using SPSS for Windows, version 13. Furthermore, in the DM CPG study we investigated whether the CPG contained 1) an evidence table, 2) a description of the grading system, 3) graded recommendations, 4) an expiry or review date? We collated data in a table and used descriptive statistics (relative frequency). 4.3.2. Evaluation of differences between primarily diagnostic and combined clinical practice guidelines We created two subgroups of DM CPGs based on their scope for investigating difference between "purely diagnostic" and "combined" CPGs in depth pair-wise comparisons were carried out using the Mann-Whitney U test with Bonferroni correction. The level of significance was set at p≤0.01 because of multiple comparisons. All analyses were performed using SPSS for Windows, version 13.
Evaluation of the fulfilment of basic diagnostic reporting standards
We assessed the presence of 1) prevalence, 2) diagnostic accuracy of tests, 3) preanalytical, and 4) analytical specifications. The frequency of this reporting specific laboratory information in different guideline subgroups was compared with the Fisher's exact test. The level of significance was set at p≤0.01 because of multiple comparisons. All analyses were performed using SPSS for Windows, version 13.
4.4.
Systematic reviewing techniques to compare methodological quality in other medical fields We systematically reviewed the literature that used the AGREE Instrument for such evaluation and compared our findings. We searched electronically in Medline in May 2007 with the following key word combinations: (("Guideline "[Publication Type] OR "Guidelines as Topic" [Mesh] OR "Guideline Adherence" [Mesh] OR "Practice Guideline "[Publication Type]) AND quality) AND AGREE) without using any language limits. Data on the topics, origin, number and publication dates as well as the AGREE domain scores of each study and collected and presented in a summary table and a diagram.
4.5.
Methods of the evaluation of relationship between methodological quality and validity of content of guidelines Two assessors extracted all laboratory-related recommendations from the 11 NSCLC guidelines selected for review. Validity of recommendations was investigated based on a published systematic review regarding the use of tumor markers and other more global laboratory tests in NSCLC. Methodological quality was assessed by AGREE Instrument with slightly modified expression of overall assessments.
RESULTS
5.1.
Applicability of the AGREE Instrument to diagnostic guidelines (Paper I) The agreement between assessors was acceptable based on statistical calculations (Table 1) . We have noted some discrepancy between statistical judgements of agreement and the comparison of each item score of each appraiser therefore we decided not to use the calculation of ICC and Cronbach's alpha in subsequent analysis, but rather we reach consensus for each item where disagreement is grater than 2 scores/item. In spite of ANOVA calculating similar ranks for the NICE and NACB CPGs, by showing no significant differences between them, their overall assessments, based on AGREE Instrument, were very different. Therefore the appraisers reached a consensus that we would hereafter use only the overall assessment method of the AGREE Instrument for characterizing the acceptance of the methodological quality of CPG, rather than the mentioned statistical methods. Assessors had judged that the AGREE Instrument is a useful tool and is applicable for the general assessment of methodological quality of CPGs in laboratory medicine as well. Surprisingly the well-known CPGs had some serious shortcomings in all appraised aspects, thus reflected need for appraising of methodological quality of all CPGs before their use. Diabetes mellitus (Paper III) Based on the assessment of methodological quality, 22 CPGs were recommended by reviewers, of which only 11 were strongly recommended and the rest "with provisos and alterations" (Table 2 ). Overall, the best performing domains were D1 "Scope and purpose". Although D4 "Clarity and presentation" scored highly only 10 CPGs (38%) were supported with tools for application. In D3, which explored the rigour of development, there are notable shortcomings in using systematic methods for searching the evidence and providing information on the literature retrieval and selection process; indicating the methods used for formulating recommendations; and giving information on the peer reviewing and updating process. Domain 2, which explored stakeholder involvement, showed lower scores. Low scores were achieved with in the "Applicability" (34%) and "Editorial independence" (39%) domains, in which each item performed very poorly. The wide spread of the minimum and maximum scores of each individual domain these data in all domains demonstrated unexpectedly large variation in CPG. 
Non-small cell lung cancer (Paper II)
Only 5 out of 11 CPGs were recommended for use by assessors and none achieved the best overall quality rating of"strongly recommend" (Table 3 ). Three CPGs were "wouldn't recommend" and for 3 CPGs the quality was difficult to assess ("unsure") by appraisers. Overall, the best performing domain was D1 "Scope and purpose" and D4 "Clarity and presentation". There were notable shortcomings in other domains which explored the rigour of development, stakeholder involvement and editorial independence. Domain 5, which explored the applicability of recommendations, showed the lowest scores. In all domains, except Domain 5, there was a large of scores.
5.3.
Causes of poor methodological quality of diabetes mellitus guidelines 5.3.1. Correlation between the characteristics and methodological quality clinical practice guidelines (Paper III)
Date of publication
Most CPGs were developed after 2002 and only 2 were developed between 1999 and 2001. Only the highest scoring D1 and D4 showed some marginal development in quality over the time scale investigated (Table 2) . However, the poor performance in D6 showed further deterioration from 2005 onwards with failures to report editorial independence and conflict of interest in the majority of CPGs.
Type of publication
There was diversity in definitions: 19 publications were labelled as CPGs or recommendations, of which 7 stated that they were evidence-based, 4 were position statements or reports, and 3 guidance documents (Table 4) . Amongst the 7 CPGs that claimed to be evidence-based 5 had evidence summaries and 6 graded their recommendations. Three CPGs that had evidence tables, however, did not define their publications as being evidence-based. Over two thirds of CPGs defined their grading system but only 16 graded their final recommendations.
Procedure for updating guidelines
Fifteen CPGs (58%) gave a timescale or expiry date (Table 4 ). The most frequent review date was 3 and 4 years. Only 10 CPGs (38%) provided adequate information on the updating process.
Sub-grouping by source
Grouping CPGs by source of publication revealed that one CPG was published in a peer-reviewed journal, 19 were available in electronic CPG databases and 6 in both sources. The CPG that was published exclusively in a peer-reviewed journal was not recommended for use by the assessors. None of the 6 CPGs published both in peerreviewed journals and CPG databases were strongly recommended. CPGs published in electronic guideline databases only, received a more favourable overall assessment. Notable difference, at a level of significance of p≤0.05, could be observed in the D5 Applicability domain only for the electronic CPGs (Table 5) .
Sub-grouping by length
A clear relationship could be demonstrated between CPG length and methodological quality (Table 5 ). Most CPGs that were not recommended were shorter and all strongly recommended guidelines were longer than 50 pages. Significant differences between these subgroups could be found for most domains with higher quality of the longer CPGs. However, the best performing CPGs, scoring >50% in the "Applicability" domain were generally longer than 50 pages and all were published in electronic databases (Table 2 and 4) Sub-grouping by origin Nine CPGs originated from the USA, 3 from Canada, 7 from the UK, one from Australia, New-Zealand and South Africa and 4 were international. The majority of the strongly recommended CPGs originated from the UK. Significant differences (p≤0.01) could be observed in fulfilling the criteria of the D2 "Stakeholder involvement" domain, with higher scores for the British CPGs.
Sub-grouping by the availability of guideline methods manual
Two thirds of CPGs had some accompanying manuals describing the methods of their development in some form. All strongly recommended CPGs had such a manual. All mean domain scores were better in the subset where these manuals were available.
Methodological quality of primarily diagnostic and combined clinical practice guidelines (Paper III)
The rate of occurrence of strongly recommended CPGs and the not recommended CPGs was also higher for the combined, than for the diagnostic CPGs (Table 5 ). The quality of purely diagnostic CPGs was not significantly different from that of combined CPGs based on their domain scores (Table 6 ).
Compliance of guidelines with basic diagnostic reporting standards (Paper III)
Only about 60 percent of the CPGs mentioned essential laboratory-specific information (Table 7) in any detail. Reporting these pieces of information was more frequent in diagnostic as compared to combined CPGs, but the difference was not statistically significant in the various CPG subgroups (Table 8) . 
5.4.
Methodological quality of clinical practice guidelines in other medical fields (Book chapter II)
We found 21 studies up till 2007 which, have investigated the quality of CPGs using the AGREE Instrument in various clinical fields (Table 9 ). The altogether 712 CPGs had recommendations in diverse medical fields. Majority of these CPGs were predominantly therapeutic. The maximum and minimum values of mean domain scores from the 21 studies are presented in a diagram in conjunction with our own results for the DM and NSCLC CPGs (Figure 2) . The heterogeneity is very large between these 21 studies. Our results for CPGs related to laboratory medicine were similar to there international findings. Despite the heterogeneity of the published data, the major shortcomings were very similar in each study and domain. The only notable difference in our finding was that the NSCLC CPGs reached lower scores in each domain, than the DM CPGs. 
5.5.
Correlation between guideline methodological quality and validity of content (Paper II) We collected the recommendations about the use of laboratory tests in these NSCLC CPGs (Table 10 ) and information from existing systematic reviews on the laboratory parameters to be measured during the pre-treatment evaluation of NSCLC patients (Table  11) . Recent systematic reviews provide no evidence that measurement of tumor markers in routine practice would improve NSCLC patients' outcomes. Only 4 CPGs, which did not recommend the use of tumor markers, were scored for validity of content as "good".
Regarding the other laboratory tests, only 5 CPGs recommended clearly most of the laboratory tests which were found to be useful by previously published systematic reviews. These CPGs were scored "good" for validity of content about laboratory tests. Results of our comparison of guideline quality versus content for each guideline are shown in Table 12 . We did not find any relationship between the quality and validity of content and scope of CPGs (containing only diagnostic or therapeutic recommendations, as well). Our results did not confirm any relationship between the date of publications and the scores of quality or the validity of content. In patients participating in therapeutic trials: hemoglobin, leukocyte counts with differential, lactate dehydrogenase, albumin, calcium, NSE Table 12 Correlation between methodological quality and validity of content of NSCLC CPGs mean scores of their evaluations, we could only compare the mean domain scores of published studies. Despite these limitations our findings depict a similar picture across studies in many medical fields independently of date of publication or origin of recommendations. Shortcomings in methodological quality are mostly due to lack of rigour or inappropriate reporting of the CPG development process, and lack of applicability and declaration of editorial independence. Our results are the first in the field of diagnostic because no studies published so far investigated the quality of diagnostic recommendations.
6.3.
Causes of poor methodological quality of diagnostic guidelines for diabetes mellitus Some studies investigated the probable reasons of methodological shortcomings but not one has evaluated these reasons in diagnostic CPGs and not one studied the reporting of laboratory related information in guidelines yet. This question was addressed by subgroup analyses of our study on DM CPGs. Our findings demonstrated that longer and electronically published CPGs and the availability of CPG development manuals yielded higher methodological scores in most AGREE domains. One simple explanation is the lack of space available for detailed and accurate reporting of CPG methodology in journals. Paradoxically, lengthy CPGs are thought to be less practical for daily use, so one may argue that the length of CPGs adversely affects implementation. In our case, CPGs that achieved high scores for "Applicability" were indeed longer documents, but they also covered additional information on organization, cost implications and monitoring of the use of recommendations in practice. All these tools help CPG implementation and thus, at least in principle, we cannot confirm that lengthy CPGs are not applicable in practice. The Conference on Guideline Standardization defined a standard for CPG reporting in order to promote quality and facilitate implementation. Such CPG reporting standards have not yet been adopted by most journals, and peer-reviewers also rarely use the AGREE or other criteria for systematic assessment of recommendations prior to publication.
In our study the quality of purely diagnostic CPGs was not significantly different from that of combined diagnostic and therapeutic CPGs. Our additional evaluation has shown that nearly half of all diagnostic CPGs do not report pre-analytical, analytical and diagnostic accuracy data, which may lead to inappropriate requesting and interpretation of tests in clinical practice. Fulfilling these criteria would be desirable in any CPGs that provide laboratory testing-related recommendations, since it is expected that practice guidelines are developed in a multidisciplinary process. Unfortunately this could not be confirmed by our study as only 41% of the criteria were fulfilled in D2 which explored the involvement of all relevant stakeholders in the CPG development process.
All CPGs that achieved higher scores in the comparison by origin were from agencies that had detailed CPG manuals which provided a clear description and standards for the development process. The availability of a CPG manual, however, does not always guarantee that CPG teams follow those processes consistently, and it has been shown that it is often not clear how decisions are made by the CPG team when arriving at final recommendations. The substantial heterogeneity, both in how the type of publication is defined and the adherence to this definition in the final presentation of the CPG, suggests that there is likely to be a disparity between the methodology CPG developers described and what is actually followed in practice. We found, for example, several CPGs that described a grading system but did not grade their final recommendations. The lack of evidence tables in CPGs that claim to be evidence-based may also point to potential deviations from the processes set in CPG manuals.
Such heterogeneity of definitions of guidelines may highlight different approaches in formulating recommendations for practice. We also found several CPGs that, while having proof of using evidence-based methods, failed to define their publication as such. This suggests that the definitions used in the international guideline community may be confusing for both guideline developers and users, and that simplification and standardization of terminology is needed. Even though guideline development methods have gradually improved and were published by several organisations, we could not demonstrate major improvements in CPG quality for most domains and in the "Editorial independence" domain even deterioration in scores was observed over time.
There are several limitations in our study. By evaluating English publications only, our results may suffer from language bias. However, several publications, including our own review of the topic, confirm no significant differences in the quality of English versus non-English publications of guidelines or trials. Since most national DM CPGs are based on or strongly influenced by international recommendations primarily published in English, we believe our results are likely to be generalizable. Shortcoming of all critical appraisal tools is that they do not differentiate between whether the publication fails certain criteria due to lack of reporting or to poor methodology and design. Therefore, our results should not be interpreted as criticisms of the truth of scientific statements or the validity of recommendations made in a given publication about DM. However, the demonstrated shortcomings in reporting and/or the methodology applied by different CPG developers could lead to distrust in and/or misuse of recommendations.
6.4.
Correlation between guideline methodological quality and validity of content A number of studies confirm the assumption that CPGs of poor methodological quality potentially transmit biased opinions that may cause unnecessary burden to patients and costs to society. Others, however, demonstrated that despite the high inconsistencies in formulating recommendations and the great variation in the supporting evidence cited, the agreement in the content of recommendations was remarkable. Our results have shown that guidelines with poor methodological quality are not necessarily invalid in their content and vice versa; high quality CPGs do not necessarily provide the best recommendations.
The discrepancy between methodological quality and clinical validity of recommendations could be explained by the authors using different pieces of evidence or differing judgements to base their statements on. The reasons for this could be manifold: (a) non-systematic searching for the evidence, (b) ignoring findings that confirm the beliefs and assumptions or the experience and practice of the guidelines development group, (c) other competing interests as priorities, or (d) considered judgements taking into account other influencing factors such as costs, organizational barriers, patients' preferences, ethics, and safety. It has to be acknowledged that the evidence is only one element in formulating recommendations. Guideline developers may down-or upgrade the strength of evidence in final recommendations if other reasons (e.g. social, economical, organizational, societal, ethical, patient perspectives, safety or legal) strongly justify it. However, considered judgement and grading should be a well-documented and transparent process so that users of CPGs understand the rationale and reasoning behind final recommendations and why and to what extent guideline teams decided to direct from research findings.
The other reason of this discrepancy might be that the quality of a guideline depends not only on the rigour of its development but also on the quality of the evidence base underlying the recommendations. A number of studies confirmed this assumption demonstrating that poor of high quality evidence was used for CPGs in different medical fields and especially in oncology, such as in CPGs for lung cancer.
Our study has a limitation because it focused on a small part of an oncology topic. Therefore our data cannot be generalized to other medical topics. The AGREE Instrument or other CPG appraisal tools can neither investigate the accuracy of the content of recommendations nor their impact on patient outcomes. Nevertheless the discrepancies found in our study between quality and content highlight the need for critical appraisal of not only the methodology but also the content of recommendation before their use in practice. Conflicting recommendations on the use of laboratory tests are likely to lead to a waste of laboratory resources and might even cause harm to patients. Effective treatment depends on the effective use of diagnostic tests, and if diagnostic recommendations are not evidence based, it is reasonable to assume that therapeutic interventions will sometimes be initiated and monitored inappropriately.
SUMMARY
In our studies we could demonstrate that:
• There is large variation in the way diagnostic recommendations in guidelines for clinical practice are developed and how methodological quality is incorporated in the development process.
• The methodological shortcomings of DM and NSCLS CPGs are very similar to those in other medical fields.
• There are serious shortcomings in involving all relevant stakeholders in the guideline development process, in the rigour of development, applicability and editorial independence and these raise concern about both the internal and the external validity of recommendations.
• The quality of purely diagnostic CPGs was not significantly different from that of combined CPGs for DM.
• Subgroup analyses of our DM study demonstrated that longer and electronically published CPGs and the availability of CPG development manuals yielded better overall methodological quality with higher scores in most AGREE domains.
• Nearly half of all DM CPGs do not report pre-analytical, analytical and diagnostic accuracy data, which may lead to inappropriate reporting and interpretation of tests in clinical practice.
• Diagnostic recommendations about tumor markers are conflicting in CPGs for the managements of NSCLS patients.
• We did not find any straight forward relationship between methodological quality and validity of content of NSCLS CPGs.
• Our findings highlight the need for critical evaluation of both the methodology and content of any CPG before recommendations are put in clinical practice.
In conclusions, we make the following recommendations for the future:
• There is a need for systematically developed, explicit recommendations based on evidence-based guideline development and reporting standards in laboratory medicine.
• To overcome the methodological shortcomings of current guidelines standardized methods for making evidence-based guideline recommendations need to be disseminated more effectively in laboratory medicine.
• Evidence should always be assessed in close collaboration between clinicians and specialists in laboratory medicine. Evidence should be only one element n formulating recommendations. Interpretation of the evidence and its translation to practical recommendations should be documented explicitly and transparently and must be free from any form of vested interest or bias
• There is a need for simplification and standardization of CPGs terminology.
• A unified system for grading diagnostic recommendations might help to improve the validity of resulting recommendations.
•
Further studies are needed to explore in depth the relationship between the scientific validity and the methodological quality of diagnostic recommendations.
• All CPGs should be critically evaluated for methodology and content before recommendations are used in clinical practice. I wish to thank Dr. Erika Kis for fruitful discussions and cooperation in other EBM topic.
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